Financials
Financial year 2025
BIPHARMA from Antwerpen, company number BE0884868444, closed financial year 2025 with a result of € 500,026 after tax. For that financial year BIPHARMA recorded a gross margin of € 632,427 and equity of € 963,676. Compared with financial year 2024, the result moved from € 193,491 to € 500,026. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 9, 2026.
€ 963,676
▲ 14% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 500,026
▲ 158% vs 2024
Profit after tax over the fiscal year.
€ 19,102
▼ 81% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 383,889 paid out
77 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,268
▼ 99% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,349
▼ 76% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 167,454 | € 208,591 | € 216,923 | € 632,427 | ▲ 192% |
| Profit after taxes | € 164,816 | € 190,249 | € 193,491 | € 500,026 | ▲ 158% |
| Equity | € 1,463,799 | € 1,654,048 | € 847,539 | € 963,676 | ▲ 14% |
| Total debts | € 314,138 | € 192,889 | € 133,064 | € 9,117 | ▼ 93% |
| Cash | € 554,458 | € 20,419 | € 100,133 | € 19,102 | ▼ 81% |
| Retained profit | € 1,042,299 | € 1,232,548 | € 426,039 | € 542,176 | ▲ 27% |
| Dividend | € 0 | € 0 | € 1,000,000 | € 383,889 | ▼ 62% |
| Balance sheet total | € 1,777,937 | € 1,846,937 | € 980,603 | € 972,793 | ▼ 1% |
Key figures of BIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BIPHARMA?
What happened at BIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Paulus de Vogel stepped down as director. NBB
- Jeroen van der Hamsvoort stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 500,026 (▲ 158% vs 2024). Source: NBB ↗
- Paulus de Vogel became a director. NBB
- Jeroen van der Hamsvoort became a director. NBB
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
From € 164,816 profit in 2022 to € 500,026 profit in 2025.
Paid € 356,733 in corporate taxes since 2022.
Best year ever: 2025, with € 500,026 profit.
Paid out € 1.4 million in dividends to the owners in total.
Management
Directors
According to the 2025 annual accounts
since 2022 · until 2028
Jeroen van der Hamsvoort
Director
since 2022 · until 2028
Establishments
Establishment units
Physical locations of this company
Neerlandweg 24
2610 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0884.868.444
- VAT number
- BE 0884.868.444
- Registered office
- Neerlandweg 24, 2610 Antwerpen
- Names & denominations
- BIPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 November 2006
- Peppol
- Active · Active since 10 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten